Enlivex (Nasdaq: ENLV) details $1.1B RAIN token holdings and NAV

Rhea-AI Filing Summary

Enlivex Ltd. reported an update on its digital asset treasury built around the RAIN token. As of July 18, 2026, net asset value per ordinary share was $66.16, and the company held 79,550,593,122 RAIN tokens with a total value of approximately $1.1 billion. Updated unaudited, mark-to-market treasury metrics are available on its public dashboard.

Enlivex describes itself as a quality longevity company advancing Allocetra, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. Alongside this clinical portfolio, it operates a prediction markets treasury strategy using the Rain protocol on Arbitrum, combining therapeutic development with exposure to the emerging prediction markets ecosystem. The company notes that expectations regarding its digital asset strategy, RAIN token markets, and clinical and regulatory outcomes involve significant risks and uncertainties.

Key Figures

NAV per ordinary share: $66.16 RAIN tokens held: 79,550,593,122 tokens RAIN treasury estimated value: approximately $1.1 billion +2 more

5 metrics

NAV per ordinary share $66.16 As of July 18, 2026 net asset value per ordinary share

RAIN tokens held 79,550,593,122 tokens RAIN token holdings as of July 18, 2026

RAIN treasury estimated value approximately $1.1 billion Estimated total value of RAIN token holdings as of July 18, 2026

NAV valuation date July 18, 2026 Date for which NAV and RAIN token holdings were reported

Announcement date July 20, 2026 Date Enlivex publicly provided the RAIN token treasury update

Key Terms

net asset value (NAV), prediction markets treasury, mark-to-market, decentralized prediction markets infrastructure

4 terms

net asset value (NAV) financial

"As of July 18, 2026, the net asset value (NAV1) per ordinary share was $66.16"

Net asset value (NAV) is the per-share value of an investment fund calculated by totaling the fund’s assets, subtracting its liabilities, and dividing the remainder by the number of outstanding shares. Think of it like a price tag on each share of a collective piggy bank: investors use NAV to see what each share is worth, to compare funds, and, for many funds, it’s the price at which shares are bought or redeemed.

prediction markets treasury financial

"a quality longevity company powered by a prediction markets treasury"

A prediction markets treasury is the pool of money, tokens or reserves held by a prediction market platform to pay out winners, provide trading liquidity and cover operating costs. Think of it like the cash register and rainy‑day fund for a betting exchange: its size and composition affect whether promises can be paid, how easily users can trade, and how risky the platform is, so investors watch it to judge solvency and financial health.

mark-to-market financial

"The updated unaudited mark-to-market treasury metrics are publicly available"

"Mark-to-market" is a method of valuing assets or investments based on their current market price, rather than their original cost or value. It helps investors see the most up-to-date worth of their holdings, much like checking the latest price of a stock before deciding to buy or sell. This approach ensures that financial statements reflect real-time value, providing a clearer picture of overall financial health.

decentralized prediction markets infrastructure technical

"the leading decentralized prediction markets infrastructure on Arbitrum"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 07/20/2026 - 08:02 AM Accepted by SEC EDGAR 07/20/2026 - 08:01 AM Learn about SEC filing dates

FAQ

What NAV per share did Enlivex (ENLV) report in its RAIN treasury update?

Enlivex reported a net asset value per ordinary share of $66.16 as of July 18, 2026. This NAV reflects mark-to-market treasury metrics that include its RAIN token holdings and provides a snapshot of balance-sheet value tied partly to the RAIN token treasury.

How many RAIN tokens does Enlivex (ENLV) hold and what is their value?

As of July 18, 2026, Enlivex held 79,550,593,122 RAIN tokens valued at approximately $1.1 billion. These holdings form a core part of its digital asset treasury strategy built around the Rain protocol and the broader prediction markets ecosystem on Arbitrum.

What is Enlivex (ENLV)'s business model beyond its RAIN token treasury?

Enlivex describes itself as a quality longevity company advancing Allocetra, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging. Alongside this therapeutic focus, it maintains a prediction markets treasury strategy using the Rain protocol for exposure to digital assets linked to prediction markets.

Where can investors track Enlivex (ENLV)'s RAIN token treasury metrics and market data?

Updated unaudited, mark-to-market treasury metrics are available on Enlivex's dashboard at https://enlivex.com/dashboard/. Additional information on the RAIN token, including exchange listings, daily trading volume and other parameters, is provided on https://coinmarketcap.com/currencies/rain/.

What key risks does Enlivex (ENLV) highlight regarding its digital asset strategy?

Enlivex notes risks from the highly volatile price, trading volume and liquidity of RAIN and other cryptocurrencies. It also cites regulatory and tax uncertainty, possible correlation between its ordinary share performance and digital assets, and broader macroeconomic, political, competitive and market factors.

Which therapeutic indication is Enlivex (ENLV) primarily targeting with Allocetra?

Allocetra is described as an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. The company also references broader market opportunities for results from its current clinical studies and related preclinical experiments.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: July 2026

Commission file number: 001-36578

ENLIVEX LTD.

(Translation of registrant’s name into English)

14 Einstein Street, Nes Ziona, Israel 7403618

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒         Form 40-F ☐

On July 20, 2026, Enlivex Ltd., a company organized under the laws of the State of Israel, issued a press release providing an update on its RAIN token holdings. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

Exhibit No.
99.1		Press Release

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Enlivex Ltd.
	(Registrant)
	By:	/s/ Oren Hershkovitz
	Name:	Oren Hershkovitz
	Title:	Chief Executive Officer

Date: July 20, 2026

2

Exhibit 99.1

Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion

● As of July 18, 2026, net asset value (NAV1) per share was $66.16

● As of July 18, 2026, Enlivex held 79,550,593,122 RAIN tokens with a total value of approximately $1.1 billion2.

Nes-Ziona, Israel, July 20, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today provided an update on its RAIN token holdings. As of July 18, 2026, the net asset value (NAV¹) per ordinary share was $66.16, and the Company held 79,550,593,122 RAIN tokens with a total value of approximately $1.1 billion².

The updated unaudited mark-to-market treasury metrics are publicly available on the Company’s website at https://enlivex.com/dashboard/. Detailed information about the RAIN token’s listing on various exchanges, daily trading volume and other parameters can be found on https://coinmarketcap.com/currencies/rain/.

About Enlivex

Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem.

Forward-looking statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to,” “goal,” and other words of similar meaning, including statements relating to the anticipated benefits of the Company’s digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company’s ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company’s plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs.

¹ Net asset value per share: the total treasury valuation divided by the total number of outstanding ordinary shares

² Valuation calculated using the closing price of the RAIN token as quoted on https://coinmarketcap.com/currencies/rain/

Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company’s digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law.

Enlivex contact

Shachar Shlosberger
CFO
Enlivex Ltd.
shachar@enlivex.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 11.3 KB